Baseline demographics and disease characteristics in the six participants
| Subject | Age, race/ethnicity sex | Baseline SLE manifestations | SLE duration at baseline | Baseline SLE medications | Baseline SLEDAI score | Week 24 SLEDAI score |
| 1 | 30–35 year old female | Transverse myelitis, alopecia, oral ulcers, pleuritis | 4.8 years | HCQ, MMF, prednisone | 6 | 0 |
| 2 | 35–40 year old female | Arthritis, alopecia, oral ulcers | 9.9 years | HCQ | 8 | 2 |
| 3 | 30–35 year old female | Arthritis, alopecia, peritonitis, angioedema | 10.5 years | Cyclosporine, prednisone | 6 | NA |
| 4 | 25–30 year old female | Rash, oral ulcers, alopecia, low complement, +dsDNA abs, nephritis | 11.7 years | HCQ, MMF, prednisone | 10 | 6 |
| 5 | 45–50 year old female | Rash, arthritis, oral ulcer | 8.7 years | HCQ, prednisone | 8 | 0 |
| 6 | 35–40 year old female | Arthritis, low complement, +dsDNA abs, leucopenia | 3.9 years | HCQ, MMF, AZA, prednisone | 11 | 5 |
Demographics of the participants is presented in column 2 with baseline lupus manifestations and disease duration are shown in columns 2 and 3. There was a wide range of disease manifestations and disease duration. Baseline medications, SLEDAI at baseline and SLEDAI at week 24 are presented in columns 5, 6 and 7.
AZA, azathioprine; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil.